...for its human skeletal muscle cell lines to Boehringer for evaluation and drug discovery research. Xcellsyz Ltd....

...GERN granted Xcellsyz a non-exclusive license to GERN's human telomerase reverse transcriptase (hTERT) technology for research...
...transcriptase (hTERT) technology for research applications and the development of research products. Under the deal, Xcellsyz...
...and equity in Xcellsyz, and is eligible for royalties. Geron Corp. (GERN), Menlo Park, Calif. Xcellsyz Ltd....

...GERN granted Xcellsyz (Newcastle, U.K.) a non-exclusive license to GERN's human telomerase reverse transcriptase (hTERT) technology...
...transcriptase (hTERT) technology for research applications and the development of research products. Under the deal, Xcellsyz...
...made using Xcellsyz's own technology. GERN will receive a cash license fee and equity in Xcellsyz...

...Diabetes and obesity company Xcellsyz (Newcastle-Upon-Tyne, U.K.) hired Brad Hoy as CEO. He replaces acting CEO...

...European high throughput drug discovery play Xcellsyz hired Dimitri Dimitriou as CEO. Dimitriou was most recently...

...000 ($362.500) in qualifying U.K. companies. The fund recently invested in cell-based drug discovery company Xcellsyz...